In addition, immunohistochemistry results suggested that there were no statistically significant correlations between the percentage of patients with PSMA-positive NECs or/and tumor cells and gender, pathological type of NSCLC, size of primary tumor, or presence or absence of lymph node metastasis (Table 1). The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.